Trials / Withdrawn
WithdrawnNCT03303313
A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients With Atypical Hemolytic Uremic Syndrome
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Cemdisiran in patients with aHUS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cemdisiran | Subcutaneous (sc) injection of Cemdisiran |
Timeline
- Start date
- 2017-09-19
- Primary completion
- 2018-09-12
- Completion
- 2018-09-12
- First posted
- 2017-10-06
- Last updated
- 2018-10-01
Locations
12 sites across 10 countries: Bosnia and Herzegovina, Canada, Estonia, Georgia, Latvia, Lithuania, Moldova, North Macedonia, Serbia, Sweden
Source: ClinicalTrials.gov record NCT03303313. Inclusion in this directory is not an endorsement.